Robert, C., Dummer, R., Gutzmer, R., Lorigan, P., Kim, K., Nyakas, M., . . . Middleton, M. (2013). Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study.
Chicagoスタイル(17版)引用形式Robert, C., et al. Selumetinib Plus Dacarbazine Versus Placebo Plus Dacarbazine as First-line Treatment for BRAF-mutant Metastatic Melanoma: A Phase 2 Double-blind Randomised Study. 2013.
MLA(9版)引用形式Robert, C., et al. Selumetinib Plus Dacarbazine Versus Placebo Plus Dacarbazine as First-line Treatment for BRAF-mutant Metastatic Melanoma: A Phase 2 Double-blind Randomised Study. 2013.
警告: この引用は必ずしも正確ではありません.